Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $5.9 million.

  • Gyre Therapeutics' Consolidated Net Income rose 10784.31% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year increase of 11279.92%. This contributed to the annual value of $16.9 million for FY2024, which is 11957.5% up from last year.
  • Latest data reveals that Gyre Therapeutics reported Consolidated Net Income of $5.9 million as of Q3 2025, which was up 10784.31% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Consolidated Net Income ranged from a high of $51.6 million in Q2 2022 and a low of -$101.8 million during Q4 2023
  • For the 5-year period, Gyre Therapeutics' Consolidated Net Income averaged around -$7.5 million, with its median value being $1.6 million (2025).
  • In the last 5 years, Gyre Therapeutics' Consolidated Net Income tumbled by 45319.52% in 2021 and then surged by 35909.27% in 2022.
  • Over the past 5 years, Gyre Therapeutics' Consolidated Net Income (Quarter) stood at -$20.3 million in 2021, then plummeted by 41.75% to -$28.8 million in 2022, then plummeted by 253.66% to -$101.8 million in 2023, then surged by 99.57% to -$433000.0 in 2024, then surged by 1470.9% to $5.9 million in 2025.
  • Its last three reported values are $5.9 million in Q3 2025, $1.6 million for Q2 2025, and $3.7 million during Q1 2025.